# Nuclide record paper-zircon-lancet-oncol-2024 (paper). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/key-papers/paper-zircon-lancet-oncol-2024/>
  a schema:ScholarlyArticle ;
  nuclide:kind "paper" ;
  schema:identifier "paper-zircon-lancet-oncol-2024" ;
  schema:name "ZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma"@en ;
  schema:description "A PET scan using a radioactively-labelled antibody could tell, without surgery, whether a suspicious kidney lump was the most common type of kidney cancer - correctly in about 9 out of 10 people."@en ;
  schema:url <https://nuclide.cc/key-papers/paper-zircon-lancet-oncol-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/39270701/>, <https://telixpharma.com/news-views/highly-accurate-telixs-phase-iii-zircon-trial-for-kidney-cancer-imaging-published-in-the-lancet-oncology/> ;
  nuclide:tag "renal cell carcinoma", "PET imaging", "CAIX" ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(24)00402-9> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, et al." ;
  nuclide:related <https://nuclide.cc/drugs/girentuximab-zr89/>, <https://nuclide.cc/technologies/caix-pet/>, <https://nuclide.cc/indications/rcc/>, <https://nuclide.cc/technologies/immuno-pet/>, <https://nuclide.cc/companies/telix/>, <https://nuclide.cc/isotopes/zr-89/> .